News Headlines Article

Medicare Panel Backs Prostate Drug
New York Times

A federal advisory committee said Wednesday that there was adequate evidence that the drug Provenge prolongs the lives of men with advanced prostate cancer, an endorsement that makes it more likely that Medicare will pay for the $93,000 treatment. The Medicare Coverage Advisory Committee voted that it had “intermediate confidence’’ in the strength of the data that the drug, developed by Dendreon, improves survival.